No Access

ESTABLISHMENT OF OVINE MODEL FOR CH-VAD IMPLANTABLE VENTRICULAR ASSIST DEVICE

Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P. R. China

E-mail Address: assosiate@sina.comt

Search for more papers by this author

LIN YANG

College of Life Science and Bio-engineering, Beijing University of Technology, Beijing, 100124, P. R. China

E-mail Address: yanglin@bjut.edu.cn

Corresponding authors.

Search for more papers by this author

HAIYANG LI

Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P. R. China

E-mail Address: ocean0203@163.com

Search for more papers by this author

XIAOTONG HOU

Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P. R. China

E-mail Address: houxiaotong@yahoo.com.cn

Search for more papers by this author

CHEN CHEN

CH Biomedical, Inc, Jiangsu 215125, P. R. China

E-mail Address: chenchen@chinaheartbmd.com

Search for more papers by this author

PENG YANG

CH Biomedical, Inc, Jiangsu 215125, P. R. China

E-mail Address: yangp@chinaheartbmd.com

Search for more papers by this author

, and

CHANGYAN LIN

Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P. R. China

E-mail Address: llbl@sina.com

Corresponding authors.

Search for more papers by this author

https://doi.org/10.1142/S021951941940027XCited by:1 (Source: Crossref)

This article is part of the issue:

A Special Selection on Biomechanics in Medical Applications – Part I;
Guest Editors: Esteban Peña Pitarch, Agnès Drochon and Eddie Y. K. Ng

Abstract

The objective of this study was to establish an ovine model for CH-VAD (CH Biomedical Inc., JiangSu, China) implantable ventricular assist device (IVAD) to evaluate experimental protocols, including anesthesia management, surgical process, autopsy criteria and a validated anticoagulation procedure. Method: IVAD was implanted into the chest of sheep without stopping the beating heart through a left thoracotomy, and the inflow cannula was connected to the left ventricular apex and the outflow cannula was anastomosed to the descending aorta. Results: Totally 23 cases were established: 6 died of an anaesthetic or surgical reasons, one died of lung infection, the other 16 cases survived for more than 15 days, among which four cases were terminated because of decrease of pump flow and the other 12 cases survived for more than 30 days. Conclusions: Sheep models suitable for implantation of CH-VAD implantable LVAD were successfully established and the appropriate safety evaluation indicators of this model were validated in the course of the animal experiments, and the survival rate of the experiments were improved gradually over time.

Keywords:

References

1. Roger VL , The heart failure epidemic, Int J Environ Res Public Health 7(4) :1807–1830, 2010. Web of Science, Google Scholar
2. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM 3rd , Long JW, Wozniak TC, Ghumman W, Farrar DJ, Frazier OH , HeartMate II Investigators: Advanced heart failure treated with continuous-flow left ventricular assist device, N Engl J Med 361(23) :2241–2251, 2009. Web of Science, Google Scholar
3. Kirklin JK, Naftel DC, Kormos RL et al., Quantifying the cardiorenal syndrome and its effect on mortality after LVAD implant: An analysis of 4,917 patients from INTERMACS, J. Heart Lung Transplant 32(4) :S133, 2013. Web of Science, Google Scholar
4. Kirklin JK, Naftel DC, Pagani FD et al., Sixth INTERMACS annual report: A 10,000-patient database, J. Heart Lung Transplant 33(6) :555–564, 2014. Web of Science, Google Scholar
5. Lambert LJ, Sas G, Dragieva N et al., Characteristics and 1-year outcomes of patients with long-term left ventricular assist devices (LVAD) in quebec compared with the INTERMACS registry, Circ Cardiovas Qual Outcomes 7(Suppl 1) :A217–A217, 2014. Google Scholar
6. Wu G, Lin C, Li H, Hou X, Chen C et al., Initial in vivo evaluation of a novel left ventricular assist device. Biomed Res Int 2015(3) :1–7, 2015. Google Scholar
7. Sajgalik P, Grupper A, Edwards BS, Kushwaha SS, Stulak JM, Joyce DL et al., Current status of left ventricular assist device therapy. Mayo Clin Proc 91 :927–940, 2016. Web of Science, Google Scholar
8. Reyes C, Chorpenning K, LaRose JA, Gomez R, Tamez D , Six-year in vitro reliability results of the HeartWare HVAD pump, ASAIO J 60(5) :541–544, 2014. Web of Science, Google Scholar
9. Farrar DJ, Bourque K, Dague CP et al., Design features, developmental status, and experimental results with the Heartmate III centrifugal left ventricular assist system with a magnetically levitated rotor, ASAIO J 53(3) :310–315, 2007. Web of Science, Google Scholar
10. McGee E, Jr. , Chorpenning K, Brown MC, Breznock E, Larose JA, Tamez D , In vivo evaluation of the HeartWare MVAD Pump, J Heart Lung Transplant 33(4) :366–371, 2014. Web of Science, Google Scholar
11. Qian K, Wang DF, Topaz S et al., World-smallest LVAD with 27g weight, 21mm OD and 5lmin $-$ 1 flow with 50mmHg pressure increase, J Med Eng Technol 31(3) :181–184, 2007. Google Scholar
12. Monreal G, Sherwood LC, Sobieski MA et al., Large animal models for left ventricular assist device research and development, ASAIO J 60(1) :2–8, 2014. Web of Science, Google Scholar
13. Gemmato CJ, Frazier OH, Tuzun E et al., In vivo evaluation of the HeartWare centrifugal ventricular assist device, Tex Heart Inst J 34(4) :406–411, 2007. Web of Science, Google Scholar
14. Ii HML, Bourque K, Gernes DB et al., The HeartMate III: Design and in vivo studies of a maglev centrifugal left ventricular assist device, Artif Organs 25(5) :386–391, 2001. Web of Science, Google Scholar